Agenus Inc
A biotech company that develops cancer treatments by rallying the body's own immune system, it makes antibody therapies that help immune cells recognize and attack tumors. Founded in 1994 as Antigenics by Dr. Garo Armen and Dr. Pramod Srivastava, it built early heat-shock cancer vaccines before renaming itself Agenus in 2011 to signal a broader mission. Its saponin-based QS-21 Stimulon adjuvant is the immune-boosting ingredient in vaccines like GSK's Shingrix shingles shot.
Bought 10.00M · Sold 791.0K
Sold 2.34M
Sold 1.11M
Granted 51.6K
Granted 3.16M · Bought 5.21M · Sold 527.0K
Granted 13.4K · Sold 6.5K
Bought 30.0K
Granted 53.1K · Bought 55.0K
Granted 53.0K
Granted 472.2K · Bought 10.0K · Sold 127.5K
Granted 385.0K · Sold 179.9K
Granted 64.8K
Granted 66.2K
Granted 64.2K · Bought 2.3K · Sold 3.7K
Granted 455.8K · Sold 201.2K
Granted 354.6K · Sold 38.7K
Granted 53.1K · Bought 10.0K
Granted 39.0K
Granted 21.9K · Bought 10.0K
Granted 408.8K · Sold 146.2K
Granted 33.4K
Bought 15.0K
Granted 112.8K · Sold 3.5K
Granted 15.4K
Granted 51.6K · Sold 50.0K
Sold 5.0K
Sold 4.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Incyte Corp10% owner · 6 transactions | — | 16.97Mas of Jun 2020 | — | 10.00M | 791.0K |
| QVT Associates GP LLC +1 co-filer10% owner · 14 transactions | — | 9.24Mas of Jan 2015 | — | — | 2.34M |
| Malik ShahzadDirector · 4 transactions | — | 1.59Mas of May 2015 | — | — | 1.11M |
| Chadarevian Gamil DeDirector · 1 transaction | — | 1.57Mas of Mar 2006 | 51.6K | — | — |
| Armen Garo HSee Remarks, Director · 267 transactions | — | 426.5K | 3.16M | 5.21M | 527.0K |
| Duncan AlexChief Technology Officer · 2 transactions | — | 165.0Kas of Jun 2018 | 13.4K | — | 6.5K |
| Hatsopoulos JohnDirector · 3 transactions | — | 130.0Kas of Feb 2009 | — | 30.0K | — |
| Wiinberg UlfDirector · 5 transactions | — | 124.1Kas of Nov 2023 | 53.1K | 55.0K | — |
| Hirsch Susan BDirector · 11 transactions | — | 118.7Kas of Nov 2023 | 53.0K | — | — |
| Sharp ShaliniDirector · 48 transactions | — | 104.3Kas of Sep 2015 | 472.2K | 10.0K | 127.5K |
| Valentine KarenChief Legal Officer · 53 transactions | — | 101.5Kas of Dec 2017 | 385.0K | — | 179.9K |
| Corvese BrianDirector · 3 transactions | — | 92.1Kas of Jun 2021 | 64.8K | — | — |
| Jeynes-Ellis Allison MDirector · 3 transactions | — | 66.2Kas of Jun 2021 | 66.2K | — | — |
| Baysal OzerChief Commercial Officer · 11 transactions | — | 58.8Kas of Dec 2017 | 64.2K | 2.3K | 3.7K |
| Wentworth KerryVP, Clinical, Reg & Qual · 51 transactions | — | 57.4Kas of Feb 2014 | 455.8K | — | 201.2K |
| O'Day Steven JChief Medical Officer · 5 transactions | — | 57.1Kas of Jun 2025 | 354.6K | — | 38.7K |
| Wright TimothyDirector · 5 transactions | — | 55.4Kas of Nov 2023 | 53.1K | 10.0K | — |
| Harrison Thomas LDirector · 5 transactions | — | 39.0K | 39.0K | — | — |
| Ballantyne Charles EvanChief Financial Officer · 3 transactions | — | 24.8Kas of Apr 2016 | 21.9K | 10.0K | — |
| Klaskin Christine MPFO & PAO · 61 transactions | — | 23.5Kas of Jun 2025 | 408.8K | — | 146.2K |
| Stein Robert BenjaminPresident R&D · 2 transactions | — | 21.0Kas of Apr 2016 | 33.4K | — | — |
| Margaret EisenDirector · 1 transaction | — | 20.0Kas of May 2008 | — | 15.0K | — |
| Buell JenniferDirector · 15 transactions | — | 19.7Kas of May 2025 | 112.8K | — | 3.5K |
| Levitsky HyamDirector · 1 transaction | — | 15.4Kas of Feb 2009 | 15.4K | — | — |
| Rothwell Timothy GDirector · 4 transactions | — | 7.4Kas of Oct 2011 | — | — | — |
| Srivastava PramodDirector · 2 transactions | — | 1.6Kas of Feb 2007 | 51.6K | — | 50.0K |
| Afeyan NoubarDirector · 1 transaction | — | 0as of Dec 2006 | — | — | 5.0K |
| Atlee Frank V IIIDirector · 1 transaction | — | 0as of Nov 2006 | — | — | 4.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +9.81M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.